NASDAQ:MLAB - Mesa Laboratories Stock Price, Forecast & News

Mesa Laboratories trades on the NASDAQ under the ticker symbol "MLAB."

Mesa Laboratories declared a quarterly dividend on Thursday, January 9th. Investors of record on Friday, February 28th will be given a dividend of $0.16 per share on Monday, March 16th. This represents a $0.64 annualized dividend and a yield of 0.24%. The ex-dividend date is Thursday, February 27th. View Mesa Laboratories' Dividend History.

Mesa Laboratories, Inc. (NASDAQ:MLAB) released its quarterly earnings results on Monday, February, 10th. The medical instruments supplier reported ($1.06) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.88 by $1.94. The medical instruments supplier earned $31.66 million during the quarter, compared to the consensus estimate of $31.05 million. Mesa Laboratories had a return on equity of 10.14% and a net margin of 4.03%. View Mesa Laboratories' Earnings History.

Mesa Laboratories is scheduled to release their next quarterly earnings announcement on Monday, June 1st 2020. View Earnings Estimates for Mesa Laboratories.

3 equities research analysts have issued 1-year target prices for Mesa Laboratories' shares. Their forecasts range from $250.00 to $275.00. On average, they expect Mesa Laboratories' share price to reach $262.50 in the next year. This suggests that the stock has a possible downside of 1.5%. View Analyst Price Targets for Mesa Laboratories.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesa Laboratories in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mesa Laboratories.

News articles about MLAB stock have been trending somewhat positive this week, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mesa Laboratories earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Mesa Laboratories.

Some companies that are related to Mesa Laboratories include Cognex (CGNX), FLIR Systems (FLIR), National Instruments (NATI), Coherent (COHR), Itron (ITRI), Badger Meter (BMI), OSI Systems (OSIS), FARO Technologies (FARO), MTS Systems (MTSC), Vishay Precision Group (VPG) and Daktronics (DAKT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Micron Technology (MU), Altria Group (MO), Exxon Mobil (XOM), Coupa Software (COUP), Gilead Sciences (GILD) and PepsiCo (PEP).

Mesa Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (10.22%), Royce & Associates LP (6.09%), Kayne Anderson Rudnick Investment Management LLC (3.63%), State Street Corp (3.33%), Artisan Partners Limited Partnership (2.05%) and Renaissance Technologies LLC (1.51%). Company insiders that own Mesa Laboratories stock include David M Kelly, Evan Guillemin, H Stuart Campbell, John Bradley Schmieder, John James Sullivan, John Sakys, Michael T Brooks, Robert V Dwyer and Seg Ventures, Llc. View Institutional Ownership Trends for Mesa Laboratories.

MLAB stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Marshall Wace LLP, Renaissance Technologies LLC, King Luther Capital Management Corp, THB Asset Management, SG Americas Securities LLC, Castleark Management LLC and Conestoga Capital Advisors LLC. Company insiders that have sold Mesa Laboratories company stock in the last year include David M Kelly, Evan Guillemin, John Bradley Schmieder and Robert V Dwyer. View Insider Buying and Selling for Mesa Laboratories.

MLAB stock was purchased by a variety of institutional investors in the last quarter, including Moody Aldrich Partners LLC, Royce & Associates LP, Thrivent Financial for Lutherans, Artisan Partners Limited Partnership, Russell Investments Group Ltd., Bank of New York Mellon Corp, Kayne Anderson Rudnick Investment Management LLC and Foundry Partners LLC. View Insider Buying and Selling for Mesa Laboratories.

Shares of MLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MLAB stock can currently be purchased for approximately $266.62.

Mesa Laboratories has a market capitalization of $1.17 billion and generates $103.14 million in revenue each year. The medical instruments supplier earns $7.48 million in net income (profit) each year or $5.37 on an earnings per share basis. Mesa Laboratories employs 366 workers across the globe.View Additional Information About Mesa Laboratories.

The official website for Mesa Laboratories is http://www.mesalabs.com/.

Mesa Laboratories' mailing address is 12100 W 6TH AVE, LAKEWOOD CO, 80228. The medical instruments supplier can be reached via phone at 303-987-8000 or via email at [email protected]